Raw data is available for doctors and patients to conduct re-analysis.

Comprehensive assessment of tumor genetic information to guide clinical treatment, covering various sample types; testing reports are issued within 7 to 10 days upon collecting qualified samples.

Professional medical and genetic teams interpret the report, striving to maximize clinical benefits.

Each report is issued with a unique anti-counterfeiting QR code to verify its authenticity.

The LIUDUS^® platform, developed through in-house patented software, machine learning models and internal data libraries, is applied throughout the entire NGS process, enabling ultra-sensitive variant detection and providing physicians and patients with reliable clinical information.